Core Viewpoint - The conflict between medical beauty platform Xinyang (SY.US) and upstream supplier of regenerative materials has escalated, with accusations regarding product sourcing and training practices [2][3] Pricing Strategy and Supply Chain Conflict - In April 2025, Xinyang launched "Miracle Youth 1.0," pricing the product at 4,999 yuan per unit, significantly lower than the supplier's guidance price of 16,800 yuan [3] - In June 2025, Xinyang's "Miracle Youth 2.0" used a product from Saint Boma, priced at 5,999 yuan, while the market average was approximately 18,800 yuan, leading to accusations of unauthorized procurement [3] Company Response and Compliance - Xinyang stated that all medical devices are sourced from legally qualified suppliers with complete traceable purchase documentation, and all clinics are legally established medical institutions [5] - The company emphasized that the era of market monopoly through registration certificate scarcity and excessive price control has ended, attributing low prices to value return through large-scale procurement and reduced marketing costs [5] Financial Performance and Transition Challenges - Xinyang, as the "first internet medical beauty stock," faces strong competition from platforms like Douyin, Xiaohongshu, and Meituan, resulting in a 19.3% year-on-year decline in information and appointment service revenue in 2024 [6] - In the first three quarters of 2025, Xinyang's revenue reached 1.063 billion yuan, a decrease of 3.36% year-on-year, with a net loss of 133 million yuan, marking a shift from profit to loss [6] - The company's offline beauty treatment services generated 427 million yuan, a 385.05% increase year-on-year, becoming the largest revenue source, surpassing traditional business for the first time [6] Industry Competition and Business Model Changes - Xinyang's aggressive pricing strategy has led to a significant reduction in profit margins, with offline service gross margins dropping to 24%, well below the industry average of over 50% [7] - In September 2025, Xinyang launched a customized version of "Plastic Beauty" (Miracle Youth 3.0) at a price of 2,999 yuan, with a core ingredient PLLA content of 75mg, only half of that in mainstream products [7] - The company's "low-price revolution" and aggressive transformation have fundamentally changed its business model, raising concerns about balancing price competitiveness with supply chain relationships and ensuring medical safety and service quality [7]

Core Viewpoint - The launch of New Oxygen's Miracle Youth Needle 3.0 at a price of 2999 yuan marks a significant price drop in the market, challenging the existing high-priced products which are generally above 10,000 yuan [1][3][4]. Pricing Strategy - New Oxygen's pricing strategy is based on gaining pricing power through collaboration with upstream manufacturers, allowing them to set a price significantly lower than competitors [1][5]. - The previous versions of the product were priced at 4999 yuan and 5999 yuan, indicating a trend of decreasing prices in the market [3][8]. Market Context - The current market for youth needles includes products from various companies, with prices typically exceeding 10,000 yuan, such as 12,800 yuan for Aivilan and 13,800 yuan for Lijinran [3][4]. - The trend of decreasing prices is expected to continue, driven by product effectiveness and user value [4]. Company Performance - New Oxygen's clinics have achieved single-month profitability, although overall profitability is still pending due to the costs associated with their middle office operations [8][9]. - The company has opened 37 clinics as of September 2023, with plans to exceed 50 by the end of the year and aims for a long-term goal of "100 cities and 1,000 stores" [9]. Financial Growth - In Q1 2023, New Oxygen's light medical beauty chain business revenue grew by 551.4%, accounting for 33.3% of total revenue, while Q2 revenue from beauty treatment services reached 144 million yuan, up 426.1% year-on-year [9].